Search

everythinglearnresearchcommunity

for

Search:↓

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Patients with GATA2 deficiency show early skin symptoms that help diagnose the condition.

Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.

Follicular Cell Implantation might become a new treatment for hair loss and could lead to advances in organ regeneration.

Xenobiotic-free progenitor cells improve wound healing and blood vessel formation.

Alopecia areata can be transferred through stem cell transplants from affected siblings.

FTY720 helps transplanted fat survive better by reducing immune rejection and improving blood vessel growth.

Permanent hair loss after a stem cell transplant can be a sign of chronic immune system attack on the scalp.

New scaffold materials help heal severe skin wounds and improve skin regeneration.

A woman's sudden hair loss three years after a bone marrow transplant was a sign of chronic graft-versus-host disease but improved with treatment.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

Standard treatment for congenital erythropoietic porphyria was ineffective over five years.

Folliculotropic mycosis fungoides has a worse prognosis than other types, with survival rates varying significantly based on subtype and organ involvement.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

Tissue engineering advancements are improving skin substitutes for better burn treatment.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.

Skin issues from chronic graft-versus-host disease greatly affect daily life, needing teamwork between blood and skin doctors.

Artificial skin grafts face immune rejection, but stem cells may improve future designs.

Mitochondrial therapy and platelet-rich plasma therapy both stimulated hair regrowth in aging mice, with mitochondrial therapy showing similar effectiveness to plasma therapy.

Graft-versus-host disease occurs when donor immune cells attack the recipient's body, causing skin, gut, and liver damage.

Skin problems are common after stem cell transplants, and early treatment by dermatologists can improve patient outcomes.

New regenerative therapies show promise for treating hair loss.

Human mesenchymal stem cells show promise for treating skin diseases, but more research is needed to improve treatments.

cGVHD often severely affects the skin, causing rapid aging and other issues.

Somatostatin may help protect hair follicles from immune attacks.

Stem cell therapy is promising for treating various health conditions, but more research is needed to understand its full potential and address challenges.

Stem cell therapy improves healing and reduces pain in cutaneous radiation syndrome.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.